Table 1.
Summary of studies evaluating alloSCT versus autoSCT in patients with intermediate-risk AML/CR1
| First author [Ref.], year of publication | Transplantation period | Patients,n |
Median age, years (range) |
Median follow-up, months (range) | AlloSCT benefit for intermediate-risk AML/CR1 |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| alloSCT | autoSCT | alloSCT | autoSCT | RFS | OS | RR | TRM | |||
| Slovak [1], 2000a | 1990–1995 | 47 | 37 | 34 (18–54) | 39 (16–55) | 57.6 (8–90) | NR | no | NR | NR |
| Suciu [33], 2003a | 1993–1999 | 61 | 104 | 35 (15–45) | 33 (15–45) | 48 (NR) | no | no | no | no |
| Cho [34], 2013 | 2002–2009 | 199 | 89 | 36 (16–65) | 42 (15–65) | 74 (6–120) | yes | no | no | NR |
| Keating [16], 2013 | 1995–2004 | 903 | 230 | 38 (19–60) | 44 (19–60) | 60 (NR) | no | no | NR | NR |
| Cornelissen [9], 2015 | 2001–2010 | 161 | 93 | 51 (40–60) | 52 (40–60) | 60 (NR) | yes | no | NR | NR |
| Saraceni [32], 2016 | 2005–2013 | 217 | 120 | 48 (18–76) | 46 (18–78) | 36 (NR) | no | no | yes | no |
| Mizutani [18], 2016 | 1995–2011 | 565 | 231 | 40 (16–74) | 47 (17–80) | 60 (NR) | no | NR | NR | NR |
| Versluis [30], 2017 | 1995–2010 | 142 | 104 | 49 (16–60) | 48 (16–61) | 77 (NR) | no | no | yes | no |
| Gorin [17], 2017 | 2005–2015 | 93 | 52 | NR | NR | 29 (NR) | no | no | no | no |
| Mizutani [35], 2017 | 1995–2011 | 173 | 177 | 39 (30–50) | 49 (39–57) | 43 (16–60) | no | no | yes | NR |
| Yao [31], 2017 | 2008–2015 | 63 | 17 | 38 (16–59) | 32.5 (16–56) | 25.9 (0.4–90.2) | no | no | no | NR |
alloSCT, allogeneic stem cell transplantation; autoSCT, autologous stem cell transplantation; AML, acute myeloid leukemia; CR1, first complete remission; RFS, relapse-free survival; OS, overall survival; RR, relapse rate; TRM, treatment-related mortality; NR, not reported.
a
Prospective.